Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Dec;66(6):999–1004. doi: 10.1038/bjc.1992.401

Intrathecal chemotherapy with ACNU for meningeal gliomatosis.

T K Yoshida 1, E Beuls 1, K Shimizu 1, A Koulousakis 1, V Sturm 1
PMCID: PMC1978030  PMID: 1457369

Abstract

ACNU [1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride], one of the chloroethylnitrosoureas (CENUs), is believed to be effective against malignant glioma when intravenously or intrathecally administered. A rat model with meningeal gliomatosis (MG) induced by an intracisternal inoculation of rat C6 or 9L glioma cells was intrathecally and intravenously treated with ACNU in order to test the feasibility of intrathecal chemotherapy with ACNU in the treatment of meningeal gliomatosis. The median survival time (MST) of the animals was significantly prolonged when ACNU was intrathecally administered at dosages of 0.5 to 1.5 mg kg-1 in the early stages of MG, i.e. within 3 days after the tumour inoculation, whereas intravenous therapy with ACNU at a dose of 15 mg kg-1 did not exhibit any efficacy in the rats inoculated with C6 glioma cells (C6-MG). Intrathecal ACNU, however, at dosages of up to 1.5 mg kg-1 failed to demonstrate any therapeutic effect in the late stage of MG, i.e. 5 days after the tumour inoculation, except in the rats inoculated with 9L brain tumour cells (9L-MG). Intravenous chemotherapy with ACNU at a dose of 15 mg kg-1 extended the MST of the 9L-MG rats more significantly in the late stage of MG than in its early stage. This points to the feasibility of intrathecal ACNU in the treatment of meningeal gliomatosis in its early stages, but not in its late stages in which intravenous ACNU might be more effective than intrathecal treatment against MG of which the parenchyma has already been deeply invaded by the tumour.

Full text

PDF
999

Images in this article

1002Figure 5
on p.1002

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arita N., Ushio Y., Hayakawa T., Nagatani M., Huang T. Y., Izumoto S., Mogami H. Intrathecal ACNU--a new therapeutic approach against malignant leptomeningeal tumors. J Neurooncol. 1988 Nov;6(3):221–226. doi: 10.1007/BF00163704. [DOI] [PubMed] [Google Scholar]
  2. Arita N., Ushio Y., Hayakawa T., Yamada K., Yoshimine T., Ko S., Mogami H. [Clinical studies of meningeal gliomatosis]. No To Shinkei. 1984 Aug;36(8):775–780. [PubMed] [Google Scholar]
  3. Barker M., Hoshino T., Gurcay O., Wilson C. B., Nielsen S. L., Downie R., Eliason J. Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1973 May;33(5):976–986. [PubMed] [Google Scholar]
  4. Benda P., Lightbody J., Sato G., Levine L., Sweet W. Differentiated rat glial cell strain in tissue culture. Science. 1968 Jul 26;161(3839):370–371. doi: 10.1126/science.161.3839.370. [DOI] [PubMed] [Google Scholar]
  5. Bignami A., Eng L. F., Dahl D., Uyeda C. T. Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res. 1972 Aug 25;43(2):429–435. doi: 10.1016/0006-8993(72)90398-8. [DOI] [PubMed] [Google Scholar]
  6. Blasberg R. G., Patlak C. S., Shapiro W. R. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977 Jul;61(4):633–641. [PubMed] [Google Scholar]
  7. Bleyer W. A. Current status of intrathecal chemotherapy for human meningeal neoplasms. Natl Cancer Inst Monogr. 1977 Dec;46:171–178. [PubMed] [Google Scholar]
  8. Deen D. F., Bartle P. M., Williams M. E. Response of cultured 9L cells to spirohydantoin mustard and X-rays. Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1663–1667. doi: 10.1016/0360-3016(79)90793-4. [DOI] [PubMed] [Google Scholar]
  9. Edwards M. S., Levin V. A., Seager M. L., Wilson C. B. Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma. Childs Brain. 1981;8(6):444–451. doi: 10.1159/000120013. [DOI] [PubMed] [Google Scholar]
  10. Flessner M. F., Dedrick R. L., Schultz J. S. A distributed model of peritoneal-plasma transport: theoretical considerations. Am J Physiol. 1984 Apr;246(4 Pt 2):R597–R607. doi: 10.1152/ajpregu.1984.246.4.R597. [DOI] [PubMed] [Google Scholar]
  11. Flessner M. F., Fenstermacher J. D., Blasberg R. G., Dedrick R. L. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol. 1985 Jan;248(1 Pt 2):H26–H32. doi: 10.1152/ajpheart.1985.248.1.H26. [DOI] [PubMed] [Google Scholar]
  12. Fulton D. S., Levin V. A., Gutin P. H., Edwards M. S., Seager M. L., Stewart J., Wilson C. B. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol. 1982;8(3):285–291. doi: 10.1007/BF00254052. [DOI] [PubMed] [Google Scholar]
  13. Gutin P. H., Levi J. A., Wiernik P. H., Walker M. D. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep. 1977 Aug;61(5):885–887. [PubMed] [Google Scholar]
  14. Gutin P. H., Weiss H. D., Wiernik P. H., Walker M. D. Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study. Cancer. 1976 Oct;38(4):1471–1475. doi: 10.1002/1097-0142(197610)38:4<1471::aid-cncr2820380404>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  15. Hitchins R. N., Bell D. R., Woods R. L., Levi J. A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987 Oct;5(10):1655–1662. doi: 10.1200/JCO.1987.5.10.1655. [DOI] [PubMed] [Google Scholar]
  16. Hustu H. O., Aur R. J., Verzosa M. S., Simone J. V., Pinkel D. Prevention of central nervous system leukemia by irradiation. Cancer. 1973 Sep;32(3):585–597. doi: 10.1002/1097-0142(197309)32:3<585::aid-cncr2820320311>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  17. Kochi M., Kuratsu J., Mihara Y., Takaki S., Inoue N., Sueyoshi N., Uemura S., Ushio Y. Neurotoxicity and pharmacokinetics of intrathecal perfusion of ACNU in dogs. Cancer Res. 1990 May 15;50(10):3119–3123. [PubMed] [Google Scholar]
  18. Levin V. A., Byrd D., Sikic B. I., Etiz B. B., Campbell J., Borcich J. K., Davis R. L. Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. Cancer Res. 1985 Aug;45(8):3810–3815. [PubMed] [Google Scholar]
  19. Levin V. A., Chamberlain M., Silver P., Rodriguez L., Prados M. Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol. 1989;23(5):301–307. doi: 10.1007/BF00292408. [DOI] [PubMed] [Google Scholar]
  20. Matsukado Y., Uemura S., Kuratsu J. [Subarachnoid dissemination of the brain tumor cells (author's transl)]. No Shinkei Geka. 1980 Dec;8(12):1113–1123. [PubMed] [Google Scholar]
  21. Nagatani M., Arita N., Ushio Y., Hayakawa T., Tzuu-Yuan H., Yoshimine T., Mori S., Mogami H. [Intrathecal ACNU against malignant leptomeningeal tumors--toxicity and therapeutic effect in experimental animals]. No To Shinkei. 1986 Nov;38(11):1071–1075. [PubMed] [Google Scholar]
  22. Rosenblum M. L., Gerosa M. A., Wilson C. B., Barger G. R., Pertuiset B. F., de Tribolet N., Dougherty D. V. Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential. J Neurosurg. 1983 Feb;58(2):170–176. doi: 10.3171/jns.1983.58.2.0170. [DOI] [PubMed] [Google Scholar]
  23. Sculier J. P. Treatment of meningeal carcinomatosis. Cancer Treat Rev. 1985 Jun;12(2):95–104. doi: 10.1016/0305-7372(85)90002-7. [DOI] [PubMed] [Google Scholar]
  24. Shapiro W. R., Posner J. B., Ushio Y., Chemik N. L., Young D. F. Treatment of meningeal neoplasms. Cancer Treat Rep. 1977 Jul;61(4):733–743. [PubMed] [Google Scholar]
  25. Takakura K., Abe H., Tanaka R., Kitamura K., Miwa T., Takeuchi K., Yamamoto S., Kageyama N., Handa H., Mogami H. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg. 1986 Jan;64(1):53–57. doi: 10.3171/jns.1986.64.1.0053. [DOI] [PubMed] [Google Scholar]
  26. Ushio Y., Arita N., Hayakawa T., Yamada K., Koh S., Nagatani M., Yoshimine T., Mogami H. Leptomeningeal dissemination of primary brain tumors in children: clinical and experimental studies. Prog Exp Tumor Res. 1987;30:194–205. doi: 10.1159/000413677. [DOI] [PubMed] [Google Scholar]
  27. Ushio Y., Shimizu K., Aragaki Y., Arita N., Hayakawa T., Mogami H. Alteration of blood-CSF barrier by tumor invasion into the meninges. J Neurosurg. 1981 Sep;55(3):445–449. doi: 10.3171/jns.1981.55.3.0445. [DOI] [PubMed] [Google Scholar]
  28. Yamada K., Hayakawa T., Ushio Y., Arita N., Kato A., Mogami H. Regional blood flow and capillary permeability in the ethylnitrosourea-induced rat glioma. J Neurosurg. 1981 Dec;55(6):922–928. doi: 10.3171/jns.1981.55.6.0922. [DOI] [PubMed] [Google Scholar]
  29. Yoshida T., Shimizu K., Mogami H., Egawa T., Sakamoto Y. [Intrathecal ACNU for the treatment of a meningeal gliomatosis model]. Gan To Kagaku Ryoho. 1987 Jan;14(1):84–90. [PubMed] [Google Scholar]
  30. Yoshida T., Shimizu K., Ushio Y., Hayakawa T., Arita N., Mogami H. Development of experimental meningeal gliomatosis models in rats. J Neurosurg. 1986 Oct;65(4):503–507. doi: 10.3171/jns.1986.65.4.0503. [DOI] [PubMed] [Google Scholar]
  31. Yoshida T., Shimizu K., Ushio Y., Hayakawa T., Kato A., Mogami H., Sakamoto Y. [Development of experimental meningeal gliomatosis models using nude mice]. Gan To Kagaku Ryoho. 1986 Sep;13(9):2745–2750. [PubMed] [Google Scholar]
  32. Yoshida T., Shimizu K., Ushio Y., Mogami H., Sakamoto Y., Egawa T. [Treatment of a rat meningeal gliomatosis model with neocarzinostatin]. No To Shinkei. 1987 Jul;39(7):615–619. [PubMed] [Google Scholar]
  33. Yoshida T., Shimizu K., Ushio Y., Mogami H., Sakamoto Y. Modulation in vitro and in vivo of ACNU resistance in a subline of C6 glioma with reserpine. J Neurosurg. 1987 Feb;66(2):251–255. doi: 10.3171/jns.1987.66.2.0251. [DOI] [PubMed] [Google Scholar]
  34. Yoshida T., Shimizu K., Ushio Y., Mogami H., Sakamoto Y. [Possibility of overcoming of ACNU resistance in an ACNU-resistant subline of C6 rat glioma]. No To Shinkei. 1986 Nov;38(11):1065–1070. [PubMed] [Google Scholar]
  35. Yoshida T., Ushio Y., Hayakawa T., Shimizu K., Mogami H., Nakata Y., Sakamoto Y. [Chemotherapy of experimental meningeal gliomatosis]. Neurol Med Chir (Tokyo) 1984 May;24(5):302–308. doi: 10.2176/nmc.24.302. [DOI] [PubMed] [Google Scholar]
  36. Yoshida T., Ushio Y., Hayakawa T., Yamada K., Kato A., Mogami H., Nakata Y. [Development of ACNU-resistant meningeal gliomatosis models: establishment of resistant rat glioma subline against ACNU]. No Shinkei Geka. 1984 Aug;12(9):1029–1036. [PubMed] [Google Scholar]
  37. Yoshimine T., Ushio Y., Hayakawa T., Arita N., Mori T. Ependymal reaction to stab wounds in rat brains -Immunocytochemical study with antiserum to astroprotein-. Neurol Med Chir (Tokyo) 1982 Jan;22(1):19–23. doi: 10.2176/nmc.22.19. [DOI] [PubMed] [Google Scholar]
  38. Yung W. A., Horten B. C., Shapiro W. R. Meningeal gliomatosis: a review of 12 cases. Ann Neurol. 1980 Dec;8(6):605–608. doi: 10.1002/ana.410080610. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES